ZBTB41 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:360023, FRBZ1, HGNC:24819, NM_194314, NP_919290, NR_135153, XM_011509507, XM_017001205, XP_011507809, XP_016856694, ZBTB41, ZNF924, zinc finger and BTB domain containing 41

Id:ENSG00000177888

Hgnc:HGNC:24819

Entrez:360023

Ensembl:ENSG00000177888

Description:zinc finger and BTB domain containing 41

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be located in nucleus. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View ZBTB41's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with ZBTB41.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using ZBTB41.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for ZBTB41.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with ZBTB41.

Results found

Linked to

	Label	Description
	GSE163297 doxorubicin 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE110709 GSK-J4 5 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195503 progesterone 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE184892 trehalose fibroblast 4 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE119424 GSE120214 TBXT brachyury inhibition 7 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE197422 GSE197424 FN1 overexpression HGC-27 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE161800 cisplatin A-549 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE163297 0 V 2 DOXORUBICIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE77829 SLIRP knockdown LNCaP 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE217452 docetaxel 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

GSE163297 doxorubicin 0 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE110709 GSK-J4 5 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE195503 progesterone 3 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE184892 trehalose fibroblast 4 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE119424 GSE120214 TBXT brachyury inhibition 7 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE197422 GSE197424 FN1 overexpression HGC-27 1 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE161800 cisplatin A-549 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE163297 0 V 2 DOXORUBICIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE77829 SLIRP knockdown LNCaP 3 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE217452 docetaxel 2 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.